LEE'S PHARM (0950.HK)
Market: HKEX |
Currency: HKD
Address: Building 20E
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. It focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
Show more
📈 LEE'S PHARM Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
200-500%
-
Net Income Growth Range (1Y):
200-500%
-
Revenue Growth Range (1Y):
25-50%
💰 Dividend History
Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
2025 |
- |
$0.025000 |
- |
2025-05-28 |
- |
Dividend payout |
Total Amount for 2025: $0.025000 |
2024 |
- |
$0.020000 |
- |
2024-09-12 |
- |
Dividend payout |
$0.010000 |
- |
2024-05-28 |
- |
Dividend payout |
Total Amount for 2024: $0.030000 |
2023 |
- |
$0.008000 |
- |
2023-09-12 |
- |
Dividend payout |
$0.010000 |
- |
2023-05-25 |
- |
Dividend payout |
Total Amount for 2023: $0.018000 |
2022 |
- |
$0.010000 |
- |
2022-09-08 |
- |
Dividend payout |
$0.031000 |
- |
2022-05-26 |
- |
Dividend payout |
Total Amount for 2022: $0.041000 |
2021 |
- |
$0.030000 |
- |
2021-09-15 |
- |
Dividend payout |
$0.031000 |
- |
2021-05-31 |
- |
Dividend payout |
Total Amount for 2021: $0.061000 |
📅 Earnings & EPS History for LEE'S PHARM
Date | Reported EPS |
---|
2026-03-25 (estimated upcoming) | - |
2025-08-26 (estimated upcoming) | - |
2025-03-27 | - |
2024-03-26 | - |
📰 Related News & Research
No related articles found for "lees pharm".